Dr. Maya Khalil
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 123
Licensed in Alabama since 2020, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 39317 (first issued 2020; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 568
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 344 | 130 |
| New patient office or other outpatient visit, 60-74 minutes | 44 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mirtazapine Other prescribers in Birmingham, AL | 47 |
| Dexamethasone Other prescribers in Birmingham, AL | 45 |
| Oxycodone Hcl Other prescribers in Birmingham, AL | 43 |
| Gabapentin Other prescribers in Birmingham, AL | 32 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Birmingham, AL | 31 |
| Eliquis (apixaban) Other prescribers in Birmingham, AL | 30 |
| Tagrisso (osimertinib mesylate) | 28 |
| Ondansetron Odt (ondansetron) Other prescribers in Birmingham, AL | 28 |
| Levofloxacin Other prescribers in Birmingham, AL | 21 |
| Triamcinolone Acetonide Other prescribers in Birmingham, AL | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $22.26 in total to this clinician.
| AbbVie Inc. | $22.26 |
|---|
| Food and Beverage | $22.26 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $351,874 in research payments for these studies, mostly to the institutions running them.
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company · Active, not recruiting · NCT04956640 - EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC
Genentech, Inc. - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098]
E.r. Squibb & Sons, L.l.c. - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
E.r. Squibb & Sons, L.l.c. - A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06161441 - A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
Eli Lilly and Company - A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic No…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.